ASTRAZENECA PHARMACEUTICALS LP

Lobbying client · Delaware · filed 2025 to 2026

Research, development, and manufacturing of pharmaceutical products

$9,860,000 Reported spend

19 Filings counted

4 Outside firms hired

23 Bills named

Spend is reported income plus in-house expenses across 19 filings. The LDA keeps a separate client record for every registrant that files for a client, so this page adds up 5 records, one per registrant listed below. Records are combined when the client name matches once case, punctuation and endings such as Inc. or LLC are set aside; for a city, county or port the state has to match as well.

Who filed for this client 5

ASTRAZENECA PHARMACEUTICALS LP $9,060,000 In-house, the client's own filings · 6 filings
W STRATEGIES, LLC $480,000 Outside firm · 6 filings
TODD STRATEGY GROUP $320,000 Outside firm · 5 filings
PRIME POLICY GROUP $0 Outside firm · 1 filing
THOLOS GOVERNMENT RELATIONS $0 Outside firm · 1 filing

Spend per registrant: fees an outside firm reported, or the costs the client reported for lobbying in-house. The rows add up to the total above.

Bills named in these filings 23

HR 946
ORPHAN Cures Act

14 filings
HR 1414
Cameron’s Law

6 filings
HR 591
Defending American Jobs and Investment Act

6 filings
HR 1262
Mikaela Naylon Give Kids a Chance Act

5 filings
HR 1990
American Innovation and R&D Competitiveness Act of 2025

5 filings
HR 1
One Big Beautiful Bill Act

4 filings
HR 2423
Unfair Tax Prevention Act

3 filings
HR 4132
Prescription Information Modernization Act of 2025

3 filings
S 864
HELP Copays Act

3 filings
S 998
Medical Supply Chain Resiliency Act

3 filings
HR 1672
Maintaining Investments in New Innovation Act

2 filings
HR 6166
Lowering Drug Costs for American Families Act

2 filings
S 1605
International Competition for American Jobs Act

2 filings
HR 1503
Prescription Information Modernization Act of 2023

1 filing
HR 4695
Unfair Tax Prevention Act

1 filing
HR 1911
To amend the Internal Revenue Code of 1986 to provide that certain payments to foreign related parties subjec…

1 filing
HR 3521
Clinical Trial Modernization Act

1 filing
HR 5376
Impacts and Outcomes for Health Career Training Act

1 filing
HR 5509
Safe Step Act

1 filing
HR 7118
Genomic Answers for Children’s Health Act of 2026

1 filing
HR 9599
SECURE 340B Act

1 filing
S 1639
American Innovation and Jobs Act

1 filing
S 3841
Last Sale Valuation Act of 2026

1 filing

Reported by year 2 years

2026 $4,280,000 7 filings
2025 $5,580,000 12 filings

Issues lobbied 8

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

Agencies and chambers lobbied 12

HOUSE OF REPRESENTATIVES 16
SENATE 16
Centers For Medicare and Medicaid Services (CMS) 9
White House Office 9
U.S. Trade Representative (USTR) 6
Health & Human Services, Dept of (HHS) 5
Commerce, Dept of (DOC) 4
Health Resources & Services Administration (HRSA) 3
Bureau of Industry and Security (BIS) 2
Intl Trade Administration (ITA) 2
Labor, Dept of (DOL) 1
Treasury, Dept of 1

Recent filings 19 total

RR

THOLOS GOVERNMENT RELATIONS

3rd Quarter (July 1 - Sep 30) 2026 · posted Sep 16, 2026

View → Q2

TODD STRATEGY GROUP

2nd Quarter (Apr 1 - June 30) 2026 · House · Senate · $80,000 income · posted Jul 20, 2026

View → Q2

W STRATEGIES, LLC

2nd Quarter (Apr 1 - June 30) 2026 · House · Senate · $80,000 income · posted Jul 20, 2026

View → Q2

ASTRAZENECA PHARMACEUTICALS LP

2nd Quarter (Apr 1 - June 30) 2026 · House · Senate · $1,680,000 expenses · posted Jul 20, 2026

View → Q1

ASTRAZENECA PHARMACEUTICALS LP

1st Quarter (Jan 1 - Mar 31) 2026 · House · Senate · $2,280,000 expenses · posted Apr 20, 2026

View → Q1

TODD STRATEGY GROUP

1st Quarter (Jan 1 - Mar 31) 2026 · House · Senate · $80,000 income · posted Apr 20, 2026

View → Q1

W STRATEGIES, LLC

1st Quarter (Jan 1 - Mar 31) 2026 · House · Senate · $80,000 income · posted Apr 20, 2026

View → Q4

TODD STRATEGY GROUP

4th Quarter (Oct 1 - Dec 31) 2025 · House · Senate · $80,000 income · posted Jan 20, 2026

View → Q4

ASTRAZENECA PHARMACEUTICALS LP

4th Quarter (Oct 1 - Dec 31) 2025 · House · Senate · $670,000 expenses · posted Jan 20, 2026

View → Q4

W STRATEGIES, LLC

4th Quarter (Oct 1 - Dec 31) 2025 · House · Senate · $80,000 income · posted Jan 20, 2026

View → Q3

TODD STRATEGY GROUP

3rd Quarter (July 1 - Sep 30) 2025 · House · Senate · $80,000 income · posted Oct 20, 2025

View → Q3

W STRATEGIES, LLC

3rd Quarter (July 1 - Sep 30) 2025 · House · Senate · $80,000 income · posted Oct 20, 2025

View → Q3

ASTRAZENECA PHARMACEUTICALS LP

3rd Quarter (July 1 - Sep 30) 2025 · House · Senate · $1,350,000 expenses · posted Oct 17, 2025

View → RA

TODD STRATEGY GROUP

3rd Quarter (July 1 - Sep 30) 2025 · posted Oct 14, 2025

View → Q2

ASTRAZENECA PHARMACEUTICALS LP

2nd Quarter (Apr 1 - June 30) 2025 · House · Senate · $1,840,000 expenses · posted Jul 21, 2025

View → Q2

W STRATEGIES, LLC

2nd Quarter (Apr 1 - June 30) 2025 · House · Senate · $80,000 income · posted Jul 18, 2025

View → Q1

ASTRAZENECA PHARMACEUTICALS LP

1st Quarter (Jan 1 - Mar 31) 2025 · House · Senate · $1,240,000 expenses · posted Apr 21, 2025

View → 1TY

PRIME POLICY GROUP

1st Quarter (Jan 1 - Mar 31) 2025 · posted Apr 21, 2025

View → Q1

W STRATEGIES, LLC

1st Quarter (Jan 1 - Mar 31) 2025 · House · Senate · $80,000 income · posted Apr 18, 2025

View →

Foreign entities disclosed 1

ASTRAZENECA PLC United Kingdom named on 1 filing · highest disclosed ownership 100% · largest disclosed contribution $0

Section 7 of the LD-2: a foreign company or government that owns part of the client, pays toward the lobbying, or benefits from it. Figures are the highest single disclosure across these filings, not a sum: the same stake is re-disclosed each quarter.

Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.